EUVIMEDEUVIMED entdecken
Crossref

4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis

Yanni Lv, Qinglong Yu, Li Zhang, Lu Chen iD

Journal of Pharmacy and Pharmacology · 2026

DOI: 10.1093/jpp/rgag007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Yanni Lv und 3 weiteren Autor:innen. Beteiligte Einrichtung: Yantai Yuhuangding Hospital, 20 Yudong Road, Yantai, Shandong Province 264099, PR China. Hauptthemen laut MEDLINE: Tamoxifen, Neuropilin-1, Drug Resistance, Neoplasm, Paclitaxel. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Tamoxifen is an endocrine therapy for breast cancer that works by competing with estradiol for estrogen receptors, but continued use of tamoxifen by patients can lead to resistance and metastasis. Studies have shown that 4-hydroxytamoxifen (4-OH-TAM), the active product of tamoxifen, promotes the malignant biological behavior of breast cancer cells, but the mechanism is not fully understood.

Methods

We investigated the effects of 4-OH-TAM on breast cancer cell stemness, paclitaxel (PTX) resistance and metastasis. Molecular mechanism studies were used to investigate the pro-cancer effects of 4-OH-TAM. Key findings Treatment with low-dose 4-OH-TAM increased the resistance of ER-positive (MCF-7 and T47D cells) and triple-negative (4T1 and MDA-MB-231 cells) breast cancer cells to PTX. In vitro and in vivo experiments showed that 4-OH-TAM enhanced stemness in T47D and 4T1 cells by upregulating the stem cell markers CD44 and CD133. Mechanistically, 4-OH-TAM enhanced breast cancer cell stemness by upregulating estrogen-related receptor alpha (ERRα) protein expression via neuropilin-1 (NRP-1). Notably, inhibition of the NRP-1/ERRα signaling pathway reversed 4-OH-TAM-induced PTX resistance and tumor metastasis.

Conclusion

4-hydroxytamoxifen enhances stemness through the NRP/ERRα pathway to enhance breast cancer cell PTX resistance and metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenNeuropilin-1Drug Resistance, NeoplasmPaclitaxelBreast NeoplasmsNeoplastic Stem CellsReceptors, EstrogenHumansFemaleAnimalsMDA-MB-231 CellsSignal TransductionMiceCell Line, TumorMCF-7 CellsNeoplasm MetastasisERRalpha Estrogen-Related ReceptorEstrogen Receptor alphaMice, Inbred BALB C

Stichwörter der Autor:innen

4-hydroxytamoxifenbreast cancerestrogen-related receptor αstemnessneuropilin-1

Substanzen

TamoxifenafimoxifeneNeuropilin-1PaclitaxelReceptors, EstrogenERRalpha Estrogen-Related ReceptorEstrogen Receptor alphaNRP1 protein, human

Autor:innen und Institutionen

  • Yantai Yuhuangding Hospital, 20 Yudong Road, Yantai, Shandong Province 264099, PR China.
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Pharmaceutical Science, 39 Science and Technology Avenue, Yantai, Shandong Province 264000, PR China.

ORCID-Profile: Lu Chen

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Lv, Y., Yu, Q., Zhang, L., & Chen, L. (2026). 4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag007

Vancouver

Lv Y, Yu Q, Zhang L, Chen L. 4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag007

BibTeX
@article{Lv2026,
  author = {Lv, Yanni and Yu, Qinglong and Zhang, Li and Chen, Lu},
  title = {4-hydroxytamoxifen enhances stemness through the neuropilin-1/estrogen-related receptor alpha pathway to enhance breast cancer cell paclitaxel resistance and metastasis},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  doi = {10.1093/jpp/rgag007}
}
Kostenlos starten →